AI Article Synopsis
- Recurrent cervical cancer poses serious health risks, especially after initial treatment, leading to the need for new therapy options.
- A phase 3 trial compared the effects of tisotumab vedotin to standard chemotherapy in 502 patients with recurrent or metastatic cervical cancer, focusing on overall survival.
- Results show that tisotumab vedotin significantly improved median overall survival (11.5 months vs. 9.5 months) and progression-free survival (4.2 months vs. 2.9 months), with a higher response rate compared to chemotherapy, despite both groups experiencing a high incidence of adverse events.
Article Abstract
Background: Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy.
Methods: We conducted a phase 3, multinational, open-label trial of tisotumab vedotin as second- or third-line therapy in patients with recurrent or metastatic cervical cancer. Patients were randomly assigned, in a 1:1 ratio, to receive tisotumab vedotin monotherapy (2.0 mg per kilogram of body weight every 3 weeks) or the investigator's choice of chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary end point was overall survival.
Results: A total of 502 patients underwent randomization (253 were assigned to the tisotumab vedotin group and 249 to the chemotherapy group); the groups were similar with respect to demographic and disease characteristics. The median overall survival was significantly longer in the tisotumab vedotin group than in the chemotherapy group (11.5 months [95% confidence interval {CI}, 9.8 to 14.9] vs. 9.5 months [95% CI, 7.9 to 10.7]), results that represented a 30% lower risk of death with tisotumab vedotin than with chemotherapy (hazard ratio, 0.70; 95% CI, 0.54 to 0.89; two-sided P = 0.004). The median progression-free survival was 4.2 months (95% CI, 4.0 to 4.4) with tisotumab vedotin and 2.9 months (95% CI, 2.6 to 3.1) with chemotherapy (hazard ratio, 0.67; 95% CI, 0.54 to 0.82; two-sided P<0.001). The confirmed objective response rate was 17.8% in the tisotumab vedotin group and 5.2% in the chemotherapy group (odds ratio, 4.0; 95% CI, 2.1 to 7.6; two-sided P<0.001). A total of 98.4% of patients in the tisotumab vedotin group and 99.2% in the chemotherapy group had at least one adverse event that occurred during the treatment period (defined as the period from day 1 of dose 1 until 30 days after the last dose); grade 3 or greater events occurred in 52.0% and 62.3%, respectively. A total of 14.8% of patients stopped tisotumab vedotin treatment because of toxic effects.
Conclusions: In patients with recurrent cervical cancer, second- or third-line treatment with tisotumab vedotin resulted in significantly greater efficacy than chemotherapy. (Funded by Genmab and Seagen [acquired by Pfizer]; innovaTV 301 ClinicalTrials.gov number, NCT04697628.).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMoa2313811 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis.
Front Immunol
January 2025
Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Introduction: Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated in real-world clinical settings.
Methods: Data from April 2019 to March 2024 based on the FDA Adverse Event Reporting System (FAERS) were extracted and analyzed.
Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know.
Ann Emerg Med
December 2024
Department of Emergency Medicine, MD Anderson Cancer Center, Houston, TX.
Article Synopsis
- Antibody-drug conjugates are a new class of cancer treatments that are becoming more widely used, but they come with various toxicities and complications that need to be managed, especially in emergencies.
- Common side effects include diarrhea, nausea, rash, and peripheral neuropathy, while severe conditions like interstitial lung disease and sinusoidal obstruction syndrome can pose serious health risks.
- Rare but critical issues include cardiac effects, ocular problems, and tumor lysis syndrome, which require careful monitoring and prompt medical intervention.
Antibody-Drug Conjugates: A Start of a New Era in Gynecological Cancers.
Curr Oncol
November 2024
Department of Oncology, Division of Medical Oncology, University of Western Ontario, London, ON N6A 5W9, Canada.
Article Synopsis
- * Over 80% of current clinical trials in this area are assessing the safety and effectiveness of ADCs, with around twenty agents under investigation, including approved ones like mirvetuximab soravtansine for ovarian cancer and tisotumab vedotin for cervical cancer.
- * While ADCs generally have manageable toxicity profiles, they can cause specific side effects, such as ocular toxicity, which can often be addressed through preventive measures like steroids and dose adjustments.
Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer.
Gynecol Oncol Rep
December 2024
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
•Infusion site extravasation injury is a rare but serious adverse event of tisotumab vedotin.•Central venous access device should be considered in patients with risk factors receiving antibody drug conjugate therapy.•Topical steroids may be used as part of supportive measures.
View Article and Find Full Text PDFSafety and efficacy of tisotumab vedotin with cervical cancers: A systematic review and meta-analysis.
J Obstet Gynaecol Res
December 2024
Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul, Turkey.
Background: Tisotumab vedotin (TV) holds promise for treating recurrence or metastatic cervical cancer (r/mCC), with recent FDA approval for second-line use in recurrent or metastatic cases. Our research aims to evaluate TV's efficacy and safety in these patients, focusing on overall survival (OS) and progression-free survival (PFS) outcomes.
Methods: We searched five electronic databases in February 2024, retrieved articles, screened them based on inclusion and exclusion criteria, and assessed their quality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!